LTRN PE Ratio & Valuation,Is LTRN Overvalued

LTRN Relative Valuation

LTRN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LTRN is overvalued; if below, it's undervalued.

Historical Valuation

Lantern Pharma Inc (LTRN) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.32. The fair price of Lantern Pharma Inc (LTRN) is between -- to -- according to relative valuation methord.

Relative Value

Fair Zone

-----

Current Price：3.67

Fair

-2.19

0.00

EV/EBITDA

Lantern Pharma Inc. (LTRN) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -0.73. The thresholds are as follows: Strongly Undervalued below -5.22, Undervalued between -5.22 and -2.98, Fairly Valued between 1.51 and -2.98, Overvalued between 1.51 and 3.76, and Strongly Overvalued above 3.76. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-1.40

EV/EBIT

Lantern Pharma Inc. (LTRN) has a current EV/EBIT of -1.40. The 5-year average EV/EBIT is -1.41. The thresholds are as follows: Strongly Undervalued below -6.92, Undervalued between -6.92 and -4.17, Fairly Valued between 1.34 and -4.17, Overvalued between 1.34 and 4.10, and Strongly Overvalued above 4.10. The current Forward EV/EBIT of -1.40 falls within the Historic Trend Line -Fairly Valued range.

0.00

Lantern Pharma Inc. (LTRN) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.

0.00

P/OCF

Lantern Pharma Inc. (LTRN) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.14. The thresholds are as follows: Strongly Undervalued below -3.86, Undervalued between -3.86 and -1.86, Fairly Valued between 2.14 and -1.86, Overvalued between 2.14 and 4.14, and Strongly Overvalued above 4.14. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Lantern Pharma Inc. (LTRN) has a current P/FCF of 0.00. The 5-year average P/FCF is -2.66. The thresholds are as follows: Strongly Undervalued below -12.28, Undervalued between -12.28 and -7.47, Fairly Valued between 2.15 and -7.47, Overvalued between 2.15 and 6.96, and Strongly Overvalued above 6.96. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Lantern Pharma Inc (LTRN) has a current Price-to-Book (P/B) ratio of 4.15. Compared to its 3-year average P/B ratio of 1.76 , the current P/B ratio is approximately 135.64% higher. Relative to its 5-year average P/B ratio of 1.82, the current P/B ratio is about 127.59% higher. Lantern Pharma Inc (LTRN) has a Forward Free Cash Flow (FCF) yield of approximately -41.88%. Compared to its 3-year average FCF yield of -34.03%, the current FCF yield is approximately 23.07% lower. Relative to its 5-year average FCF yield of -25.31% , the current FCF yield is about 65.44% lower.

3.94

P/B

Median3y

1.76

Median5y

1.82

-41.88

FCF Yield

Median3y

-34.03

Median5y

-25.31

Competitors Valuation Multiple

The average P/S ratio for LTRN's competitors is 0.00, providing a benchmark for relative valuation. Lantern Pharma Inc Corp (LTRN) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of LTRN increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of LTRN in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is Lantern Pharma Inc (LTRN) currently overvalued or undervalued?

What is Lantern Pharma Inc (LTRN) fair value?

LTRN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Lantern Pharma Inc (LTRN) is between to according to relative valuation methord.

How does LTRN's valuation metrics compare to the industry average?

What is the current P/B ratio for Lantern Pharma Inc (LTRN) as of Dec 16 2025?

As of Dec 16 2025, Lantern Pharma Inc (LTRN) has a P/B ratio of 4.15. This indicates that the market values LTRN at 4.15 times its book value.

What is the current FCF Yield for Lantern Pharma Inc (LTRN) as of Dec 16 2025?

As of Dec 16 2025, Lantern Pharma Inc (LTRN) has a FCF Yield of -41.88%. This means that for every dollar of Lantern Pharma Inc’s market capitalization, the company generates -41.88 cents in free cash flow.

What is the current Forward P/E ratio for Lantern Pharma Inc (LTRN) as of Dec 16 2025?

As of Dec 16 2025, Lantern Pharma Inc (LTRN) has a Forward P/E ratio of -2.31. This means the market is willing to pay $-2.31 for every dollar of Lantern Pharma Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Lantern Pharma Inc (LTRN) as of Dec 16 2025?

As of Dec 16 2025, Lantern Pharma Inc (LTRN) has a Forward P/S ratio of 0.00. This means the market is valuing LTRN at $0.00 for every dollar of expected revenue over the next 12 months.

LTRN Valuation

LTRN Valuation

LTRN Relative Valuation

Historical Valuation

Competitors Valuation Multiple

Performance Decomposition

People Also Watch

Frequently Asked Questions

Is Lantern Pharma Inc (LTRN) currently overvalued or undervalued?

What is Lantern Pharma Inc (LTRN) fair value?

How does LTRN's valuation metrics compare to the industry average?

What is the current P/B ratio for Lantern Pharma Inc (LTRN) as of Dec 16 2025?

What is the current FCF Yield for Lantern Pharma Inc (LTRN) as of Dec 16 2025?

What is the current Forward P/E ratio for Lantern Pharma Inc (LTRN) as of Dec 16 2025?

What is the current Forward P/S ratio for Lantern Pharma Inc (LTRN) as of Dec 16 2025?